Ssion on 23 November 2013, Dr Anthony Oyekunle presenting on behalf of his colleague, Dr MA Durosinmi of your Obafemi Awolowo University, Ile-Ife, Nigeria, sought to bring into focus the challenges related with managing myelodysplastic syndromes (MDS) in Africa in the face of inadequate diagnostic choices and challenges of classification and provision of suitable therapy. He observed that MDS usually are not uncommon in Africa, but that the clinical Levamlodipine besylate MedChemExpress features are related to published reports from other parts with the world. Diagnosis is restricted to morphologic examination of peripheral blood and marrow cells, whilst facilities like cytogenetics and immunophenotyping of tumour cells are very limited, specially in the majority of SSA nations. FAB classification would be the norm in most of the centres. The much more all-encompassing WHO classification approach was limited to a couple of centres within the North and South Africa, hence creating stratification of individuals into risk groups determined by International Prognostic Scoring Method not possible. Dr Durosinmi expressed the hope that efforts could be produced to upgrade levels of haematologypathology laboratories in SSA to hightech requirements with facilities for IHC, immunophenotyping, cytogenetics, and molecular pathology methods, so as to enable better characterisations of haematological neoplasia, which includes MDS. Chronic myeloid leukaemia In his presentation at the Free of charge Communication Of Abstracts II of 22 November 2013, titled `Survivorship in Nigeria Patients With Chronic Myeloid Leukemia: A study of 527 Individuals More than ten years’, Dr Anthony Oyekunle in the Obafemi University Teaching Hospital, Ile-Ife, Nigeria, observed that the advent of your tyrosine kinase inhibitor (TKI) had markedly changed the prognostic outlook for sufferers with Ph+ andor BCR-ABL1+ chronic myeloid leukaemia (CML). The study was made to assess the OS of Nigerian patients with CML on imatinib therapy. All CML patients treated within the institution on imatinib from July 2003 to June 2013 have been reviewed. The median age of your patients was 37 PubMed ID:http://www.ncbi.nlm.nih.gov/pubmed/21338496 (range: 107) years, and the gender distribution was malefemale = 320207; 472 have been in chronic, 47 in accelerated, and seven in blast phase; 442 patients are alive by June 2013, with median survival of 105.7 (95 CI, 91.519.9) months; and OS at 1, two, and 5 years were 95 , 90 , and 75 , respectively, with the survival in CP getting considerably greater (p 0.0001) compared with these in AP or BP (107.three, 74.7, and 53.7 months, respectively). Immediately after ten years of follow-up, imatinib monotherapy continues to provide impressive survival outcomes among Nigerian CML individuals. However, the patients have no access to second line TKIs, possibly accounting for the reduced survival when compared with outcomes in Western populations. Within the query period, Dr Oyekunle described various complications of hyperleucocytosis that was widespread at presentation, frequently related with organ impairment, including vision and hearing loss, in some cases reversible by lowering in the white blood count. Inside a poster presentation on 21 November 2013 titled `Unusual Presentations of Chronic Myeloid Leukaemia’, Dr Amma Benneh-Akwasi Kuma described many individuals presented with hearing loss and priapism as uncommon presentation of CML. They constituted eight.3 in the sufferers noticed at the centre. These manifestations of hyperleucocytosis connected organ failure constitute a source of compromise of quality of life that may be prevented by ea.